80963-12-8

Basic information

• Product Name: L-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 1-methyl 4-(phenylmethyl) ester
• CAS NO: 80963-12-8
• Molecular Formula: C17H23NO6
• Molecular Weight: 337.373
• Mol File: 80963-12-8.mol
• Article Data: 30

Chemical Properties

• CAS DataBase Reference: L-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 1-methyl 4-(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 1-methyl 4-(phenylmethyl) ester(80963-12-8)
• EPA Substance Registry System: L-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 1-methyl 4-(phenylmethyl) ester(80963-12-8)

Safety Data

• Hazardous Substances Data: 80963-12-8(Hazardous Substances Data)

Upstream product

• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 79-22-1 methyl chloroformate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 13726-67-5 Boc-Asp-OH 
• 100-51-6 benzyl alcohol 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 186581-53-3 diazomethane 
• 51186-58-4 4-benzyl Boc-D-aspartate 

Downstream Products

• 153460-97-0 Asp-α-OMe-β-OBzl 
• 659747-10-1 Boc₂-Asp(OBn)-OMe 
• 1449476-12-3 1-benzyl 4-methyl (S)-3-((tert-butoxycarbonyl)amino)-2,2-dimethylsuccinate 
• 869587-11-1 C₂₃H₃₀ClN₅O₇S 
• 869587-10-0 C₁₈H₂₂ClN₃O₇S 
• 869587-09-7 C₁₉H₂₄ClN₃O₇S 

Relevant articles and documents

Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome

Treatment of tuberculosis (TB) currently takes at least 6 months. Latent Mycobacterium tuberculosis (Mtb) is phenotypically tolerant to most anti-TB drugs. A key hypothesis is that drugs that kill nonreplicating (NR) Mtb may shorten treatment when used in combination with conventional drugs. The Mtb proteasome (Mtb20S) could be such a target because its pharmacological inhibition kills NR Mtb and its genetic deletion renders Mtb unable to persist in mice. Here, we report a series of macrocyclic peptides that potently and selectively target the Mtb20S over human proteasomes, including macrocycle 6. The cocrystal structure of macrocycle 6 with Mtb20S revealed structural bases for the species selectivity. Inhibition of 20S within Mtb by 6 dose dependently led to the accumulation of Pup-tagged GFP that is degradable but resistant to depupylation and death of nonreplicating Mtb under nitrosative stress. These results suggest that compounds of this class have the potential to develop as anti-TB therapeutics.

MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R', R", X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Batch and Continuous-Flow One-Pot Processes using Amine Diazotization to Produce Silylated Diazo Reagents

A novel synthesis of trimethylsilyldiazomethane (TMSCHN2) by diazotization of trimethylsilylmethylamine (TMSCH2NH2) is reported using batch and continuous flow synthesis. The latter affords a daily production of 275 g (2.4 mol) of TMSCHN2. Other silylated methylamines were also successfully reacted under the developed reaction conditions to furnish various silicon-bearing diazomethane reagents. The applicability of the process is highlighted by disclosure of batch and continuous flow one-pot esterification and 1,3-dipolar cycloaddition processes. Furthermore, the high-yielding esterification of carboxylic acids with silylated and substituted methylamines in continuous flow is disclosed. Finally, work-up and purification procedures are reported for the preparation of a 2-MeTHF solution of TMSCHN2, which can be used in rhodium-catalyzed methylenation and homologation reactions.